Background {#Sec1}
==========

Extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-PE) infections poses a unique challenge to healthcare, as it is associated with mortality and morbidity \[[@CR1]\]. These pathogens are increasingly implicated as causes of both community and hospital-acquired infections but even in the absence of infection, colonization with Extended-spectrum β-lactamase (ESBL) producing bacteria is a reason for concern \[[@CR2], [@CR3]\]. In hospital settings, gastrointestinal carriage of ESBL, is the main reservoir of these organisms associated with high risk for developing self and cross infections \[[@CR4]\].

ESBL-PE carriage and infections varies from different geographical locations, individual hospitals and different clinical conditions \[[@CR5], [@CR6]\]. A recent study from Ethiopia reported prevalence of ESBL-PE colonization to be 52% among hospitalized patients \[[@CR7]\]; admission unit, number of beds and number of patients per room were reported as factors associated with carriage of ESBL-PE in that study. Several studies in East Africa have also documented high rates of ESBL-PE from clinical settings \[[@CR8], [@CR9]\].

In Tanzania, some few studies have been conducted, mostly focusing on infections caused by ESBL producers among different populations, from children to adults with different clinical conditions \[[@CR10], [@CR11]\], but little is known about carriage rate of these pathogens among hospitalized patients where cross contamination can occur. In addition, there is also limited information about carriage of ESBL producing pathogens among adult patients with diarrhea in the study area which is important to know since ESBL production can also be observed in pathogens causing diarrhea such as, diarrhogenic *E.coli* \[[@CR12], [@CR13]\]. Therefore, this study aimed to investigate ESBL-PE fecal carriage among hospitalized patients including those with diarrhea, and determine factors associated with their carriage in various referral hospitals in Dar es Salaam.

Methods {#Sec2}
=======

Study design and settings {#Sec3}
-------------------------

This was a cross sectional study conducted from May to July 2017 in three hospitals, in Dar es Salaam, Tanzania. The study sites included Muhimbili National hospital (MNH) the main specialized tertiary hospital with 1500-bed capacity, admitting 150--180 patients per day of which 2% are due to diarrheal disease. In addition, Amana and Temeke, regional referral hospitals with 250--300 bed capacity each, admitting 50--70 patients per day of which 6--7% are due to diarrheal diseases.

Study population, sample size and sampling procedure {#Sec4}
----------------------------------------------------

A total of 196 adult patients aged 18 years and above who were admitted in medical wards, Intensive Care Unit (ICU) and isolation wards for more than 24 h were randomly selected and consecutively enrolled in this study.

Data collection {#Sec5}
---------------

Structured questionnaires were used to collect study participants' clinical and demographic information. Information recorded included; age, sex, admission unit, diarrhea status, antibiotic use in the past 3 months, hospitalization history in the past 3 months, history of invasive procedures in the past 3 months and co-morbidities.

Specimen collection {#Sec6}
-------------------

Trained nurses collected rectal swabs from consented participants and immediately put in Cary Blair transport media. The specimens were transported in a cool box with ice packs to Microbiology and Immunology Bacteriology research laboratory at Muhimbili University of Health and Allied Sciences (MUHAS) for processing.

Laboratory investigations {#Sec7}
-------------------------

In the laboratory, rectal swabs were cultured immediately on MacConkey agar supplemented with Ceftazidime 2 μg/ml and incubated aerobically at 37 °C for 24 h as a screening test for ESBL-PE \[[@CR14]\]. Isolated bacteria were identified based on colonial morphology, Gram staining and a set of conventional biochemical tests which included, Indole, Citrate, Sulphur Indole Motility (SIM) as described elsewhere \[[@CR15]\] and API 20E tests.

Isolated organisms in screening test were potentially considered as ESBL-PE; however, they were further confirmed by double disk diffusion method \[[@CR16]\]. Briefly, both ceftazidime (30 μg) and cefotaxime (30 μg), alone and in combination with clavulanate (10 μg) were placed into inoculated Muller Hinton Agar (MHA) plate with test organism and incubated at 37 °C aerobically for 18 h. The zones of inhibition were observed and interpreted according to Clinical and Laboratory Standards Institute (CLSI) 2015 guidelines. ESBL-PE was confirmed when there was ≥5 mm increase in a zone diameter for either antimicrobial agent tested in combination with clavulanate versus when tested alone \[[@CR16]\]. *Klebsiella pneumoniae* ATCC 700603 was used as a positive control.

Antibiotic susceptibility test {#Sec8}
------------------------------

The confirmed ESBL-PE isolates were tested for antimicrobial susceptibility using Kirby-Bauer disk diffusion method according to CLSI guidelines \[[@CR16]\]. Briefly, homogenous colonial suspensions were prepared using 3--5 colonies from a pure culture comparable to 0.5 McFarland turbidity standard. Standardized suspensions were inoculated on MHA, and then incubated at 37 °C aerobically for 24 h. The zones of inhibition were interpreted according to CLSI guidelines. *E. coli* ATCC 25922 was used as a positive control organism. The disks used included: chloramphenicol (20 μg), gentamicin (10 μg), ciprofloxacin (5 μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg), tetracycline (30 μg) (Oxoid, UK).

Data analysis {#Sec9}
-------------

Data analysis was performed using statistical package for social science (SPSS) version 20. Categorical variables were summarized in a form of frequencies and percentages. Fisher's exact test was employed to compare the associated factors for ESBL-PE. *P*-value \< 0.05 was considered as statistically significant. Binary simple logistic regression was first performed to determine the factors associated with ESBL-PE followed by multivariable regression model to determine factors independently associated with ESBL-PE carriage. Adjusted odds ratio was used to describe strength of association at 95% confidence intervals. *P*-value \< 0.05 was considered as statistically significant.

Results {#Sec10}
=======

Description of study participants {#Sec11}
---------------------------------

A total of 196 inpatients were enrolled, with age range from 18 to 62 years and median age of 25 (IQR: 18--30) years. Half of the study participants were aged between 18 and 27 years, and those above 57 years were the least (0.5%). Most of participants 61.7% (121/196) were females and Medical ward unit contributed majority of patients accounting for 78.6%. Nearly half of participants (46.9%) had history of previous antibiotic use in the past 3 months and 18.4% had history of invasive procedures in the past 3 months majority of them (55.6%) being catheterization. Seventy-nine patients (40.3%) had diarrhea and 36 patients (18.4%) were HIV positive (Table [1](#Tab1){ref-type="table"}). Table 1Socio-demographics and clinical Characteristics of study participantsVariablesFrequency/MedianPercentage (%)**Median age 25Age group in years** 18--279850.0 28--376835.0 38--472211.0  \> 4784.0**Sex** Female12167.7 Male7535.3**Study Site** Temeke16684.7 Amana2010.2 MNH105.1**Admission Unit** Medical ward15478.6 Isolation Unit3517.9 ICU73.5**Diarrhea Status** Yes7940.3 No11750.7**Antibiotic use in the past 3 months** Yes9246.9 No10453.1**Hospitalization in the past 3 months** Yes7035.8 No12664.2**Invasive procedure in past 3 months** Yes3618.4 No16081.6**Type of Invasive procedure** Catheterization2055.6 Surgery1644.4**HIV status** Positive3618.4 Negative16081.6

Distribution of ESBL producing Enterobacteriaceae carriage {#Sec12}
----------------------------------------------------------

Screening and phenotypic testing of isolates obtained from rectal swab specimen for ESBL-PE revealed that the overall fecal carriage of ESBL-PE was 59.7% (117/196). Majority of study participants colonized by ESBL-PE aged between 38 and 47 years (68%) and there was no significant difference in carriage between the age groups. Diarrheic patients 57 (72%) had higher colonization rate than those without diarrhea and the difference was statistically significant (*p* = 0.01). There was also a significant high carriage in patients admitted at Amana hospital (80%), compared to Temeke hospital and Muhimbili National hospital (*p* = 0.004). Further analysis stratification revealed that higher carriage rate in patients admitted in medical wards (61%) compared to ICU (57.1%) and isolation units (60%) (*p* = 0.01) (Table [2](#Tab2){ref-type="table"}). Table 2Distribution of ESBL producing Enterobacteriaceae among study participantsCharacteristics***N*** = 196Proportion of ESBL-PE carriagen (%)*p*-value**Overall 59.7%Gender** Male7543 (57.3)0.780 Female12174 (61.2)**Age groups (years)** 18--279856 (57.1) 28--376842 (61.8) 38--472215 (68.2)0.592  \> 4784 (50.0)**Study Site** Temeke16695 (57) Amana2016 (80)0.004 MNH106 (60)**Study Unit** Medical Ward15492 (61) Isolation Ward3521 (60)0.001 ICU74 (57.1)**Diarrhea Status** Yes7957 (72)0.001 No11760 (53.1)

Bacteria isolates and antimicrobial resistance pattern of ESBL-PE {#Sec13}
-----------------------------------------------------------------

Among 131 bacteria isolates confirmed as ESBL producers, *E coli* (68.7%) and *K. pneumoniae* (28.2%) were the most frequent isolated bacteria. All isolated ESBL-PE showed high co-resistance to antibiotics tested (Table [3](#Tab3){ref-type="table"}). Highest resistance totrimethoprim/sulfamethoxazole (\> 85%) was observed in all isolates. *E. coli* displayed high rates of resistance to Gentamycin (82.1%), Ciprofloxacin (66.3%, Chloramphenicol (77.9%) trimethoprim/sulfamethoxazole/ (85.3%) and Tetracycline (84.2%). Table 3Antimicrobial resistance pattern of isolated ESBL-PEAntibiotic***E. coli*** % (***N*** = 90)***K. pneumoniae*** % (***N*** = 37)***K. oxytoca % (N = 3)***Gn82.182.466.7Cip66.373.566.7C77.967.666.7Sxt85.397.1100Tet84.291.2100*Gn* gentamicin, *Cip* ciprofloxacin, *C* chloramphenicol, *Sxt* trimethoprim/sulfamethoxazole/, *Tet* Tetracycline

Factors associated with carriage of ESBL-PE {#Sec14}
-------------------------------------------

Analysis was performed to determine the factors associated with carriage of ESBL-PE. Patients exposed to antibiotics up to 3 months prior to hospitalization were significantly associated with colonization by ESBL-PE (cOR 10.7, 95% CI, 2.90--39.42, *p* = 0.00). There was no significant association between carriage of ESBL-PE and patients with history of previous hospital admission in the past 3 months as well as HIV status. On multivariable analysis, previous antibiotic use for the past 3 months was found to be independently associated with the carriage of ESBL-PE (aOR 14.65, 95% CI 3.07--69.88, *p* = 0.01) (Table [4](#Tab4){ref-type="table"}). An additional excel file describes all results in more detail (see additional file [1](#MOESM1){ref-type="media"}). Table 4Univariate and Multivariate analysis of factors associated with fecal carriage of ESBL producing EnterobacteriaceaeCharacteristics***N*** = 129n (%)\
=117Proportion of ESBL carriageUnivariateMultivariatecOR (95%)***p*** valueaOR (95%)***p*** value**Gender**1^a^ Male4843 (89.6) Female8174 (91.4)1.23 (0.37--4.11)0.74**Age group in years**116105 (90.5)1^a^1312 (92.3)1.26 (0.15--10.60)0.83**Antibiotic use in the past 3 months** No1610 (62.5)1^a^ Yes113107 (94.7)10.7 (2.90--39.42)0.0014.65 (3.07--69.88)0.01**Hospitalization in the past 3 months** No8778 (89.7)1^a^ Yes4239 (92.9)1.50 (0.38--5.86)0.56**Invasive procedures in the past 3 months** No9587 (88.4)1^a^ Surgery1312 (92.3)1.26 (0.15--10.61)0.83 Catheterization2118 (85.7)1.833 (0.45--7.43)0.4**Chronic disease** No12090 (75.0)1^a^ Yes (HIV/AIDS, PTB, Diabetes)2927 (92.3)1.30 (0.27--6.28)0.75N: Total number of patients subjected to confirmatory ESBL test, n: number of patients confirmed to carry ESBL producing pathogens, 1^a^: reference category, *cOR* crude odds ratio, *aOR* adjusted odds ratio, *HIV* Human Immunodeficiency Virus, *AIDS* Acquired Immunodeficiency Syndrome, *PTB* Pulmonary Tuberculosis

Discussion {#Sec15}
==========

In the present study we demonstrate high carriage rate of ESBL producing pathogens among hospitalized patients which is associated with previous antibiotic use. We further demonstrate high rates among patients with diarrhea compared to patients admitted with other conditions. The overall carriage rate (57.9%) in our study is comparable to findings from hospitalized adults in Ethiopia (52%) and Rwanda (50%) \[[@CR7], [@CR17]\]. However, our finding is slightly higher compared to that reported among hospitalized patients by Sabrina et al. in Dar es Salaam, Tanzania \[[@CR11]\]. Potential reasons for the observed difference include several factors such as; different ESBL detection techniques and specimen used, whereas in a study by Sabrina et al. they used urine specimen and ESBL-E test strip for ESBL detection. Furthermore the carriage rate in our study is also higher compared to that reported among hospitalized children in Dar es Salaam, Tanzania \[[@CR18]\]. This difference may be accounted for by the difference in study population, whereby the participants in that study were children versus adults in our study. Being adults, our study participants are likely to have been exposed to risk factors for carriage of ESBL-PE, like previous hospitalization and antibiotic use including self-prescription compared to children. In Uganda, a much higher colonization rate of 62% has been reported \[[@CR19]\]. The variation between our study and this study may be due to differences in study population, specimen taken, clinical conditions of the participants, factors which are known to cause variation in ESBL-PE colonization patterns as documented by others \[[@CR20], [@CR21]\].

Among the ESBL-PE colonized patients in our study, those with diarrhea had higher carriage rate compared to those without diarrhea. These results are similar to what others have reported \[[@CR6], [@CR22]\]. However, in a study done among children by Tellevic and his colleagues, children hospitalized due to diarrhea had lower carriage rate compared to those hospitalized due to other diseases, probably because the latter group included children with many diverse conditions \[[@CR18]\]. The pattern observed in our study can be explained by the fact that diarrhea cause changes in the gut microbiota which provides conducive environment for exchange of resistance genes between inter and intra species including the indigenous organisms \[[@CR23]\].

In an attempt to investigate factors associated with ESBL-PE carriage, previous antibiotic use in the past 3 months was identified as a significant factor associated with carriage of ESBL. Our findings are in agreement with previous studies done in Rwanda \[[@CR17], [@CR24]\]. This observation might be reflecting the result of irrational use of these antibiotic agents in the study population that eventually may lead to high selection pressure of resistant bacteria.

In line with reports from Sudan \[[@CR25]\] and Mali \[[@CR26]\], *Escherichia coli* was the most predominant ESBL producer isolated in our study. Cross-resistance of ESBLs to other drug classes such as aminoglycosides and fluoroquinolones has been previously documented \[[@CR27]--[@CR29]\]. Findings from this study corroborates with that, as it indicated a high co-resistance pattern to those antibiotic classes in all tested isolates. This pattern is however higher than findings from Ethiopia \[[@CR7]\]. This may be explained by the fact that the plasmids carrying genes for ESBL production which was observed to be high in this study was also carrying co- resistance genes for other antibiotics. Highest resistance of antibiotics was observed in trimethoprim/sulfamethoxazole/ and tetracycline in all isolated ESBL-PE, these findings are consistent with reports from one study in Uganda \[[@CR30]\]. The high resistance pattern observed in this study could reflect frequent use of over the counter medicine and self-medication practices in the study settings. This result indicates the need for guided treatment following culture results. A limitation of this study was a failure to perform molecular tests for characterization of ESBL genes from isolated pathogens.

Conclusion {#Sec16}
==========

This study revealed high prevalence of fecal carriage of ESBL-PE among hospitalized patients especially among those with diarrhea. Previous antibiotic use was associated with carriage of ESBL-PE. ESBL producing isolates expressed high resistance to other commonly used antibiotics.
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###### 

**Additional file 1.** Raw data for ESBL-PE among adult patients in Dar es Salaam Tanzania. Additional file [1](#MOESM1){ref-type="media"} is an excel spreadsheet with the data obtained from admitted adult patients in three different hospitals in Dar es salaam Tanzania. All provided data was analyzed using SPSS software and generated results reported in this manuscript.
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